Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03679975 · ClinicalTrials.gov registry record · Phase 2
Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Aquestive Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03679975 is a Phase 2 study that was terminated before completion, run by Aquestive Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT03679975, a Phase 2 study, was terminated before completion, sponsored by Aquestive Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the effect, if any, of a single 50 mg dose of Riluzole Oral Soluble Film (ROSF) on swallowing safety in individuals with amyotrophic lateral sclerosis.
Interventions
- DRUG Riluzole Oral Soluble film (ROSF) 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-04-04 |
| Est. Completion | 2018-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03679975
The ClinicalTrials.gov registry entry for NCT03679975 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aquestive Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Riluzole Oral Soluble film (ROSF) 50 mg is the first listed.
NCT03679975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03679975 about?
NCT03679975 is a clinical study titled "Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)". The primary objective is to evaluate the effect, if any, of a single 50 mg dose of Riluzole Oral Soluble Film (ROSF) on swallowing safety in individuals with amyotrophic lateral sclerosis.
What is the current status of trial NCT03679975?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2018-04-04. Estimated completion is 2018-12-21.
What interventions are being tested in trial NCT03679975?
The interventions under investigation include: Riluzole Oral Soluble film (ROSF) 50 mg (DRUG).
Who is sponsoring clinical trial NCT03679975?
This trial is sponsored by Aquestive Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.